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sulphonylureas were less likely to be persistent than those initiated on metformin 
(OR= 0.50; 95%CI= 0.45 to 0.54; p< .0001). ConClusions: Persistence amongst newly 
treated T2DM patients appears to be low. Type of OHM, age and scheme were all 
significantly associated with persistence. Prescribers should pay particular atten-
tion to newly treated patients covered under the GMS scheme, at the extremes of 
age and those initiated on sulphonylureas.
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objeCtives: The impact of memory problems (MPs) on patient’s insulin taking 
behavior, functioning, well-being and diabetes management is not well under-
stood. Methods: A 5 country web-based survey was conducted. MPs were defined 
as: unintentionally forgetting (UF) to take insulin, questioning whether or not 
insulin had been taken (QT), or questioning how much insulin dose was taken 
(QD). Data from Canadian respondents were analyzed and compared to the other 
countries (US, UK, Germany, and China). Results: A total of 350 respondents in 
Canada completed the survey (74.0% Type 1, 52.0% male, mean age of 37.1 years, 
mean age of diabetes onset of 24.2). The prevalence of MPs was 60.6% (UF), 76.3% 
(QT) and 44.6% (QD) in the past month with only approximately 1/3 being confi-
dent they knew what to do when having an MP. Between 21.5% (QT) and 37.4%(UF) 
tested their blood glucose and 32.6% (QD) – 51.6% (QT) skipped their insulin dose 
and waited for next scheduled dose when experiencing a MP, requiring, on aver-
age, between 8.5 (QT)–19.1 (UF) hours for return to normal blood glucose ranges. 
Patients conducted between 1.9 (QT) –5.0 (UF) extra BG monitoring tests the week 
following the MP and reported moderate negative impacts on their ability to 
work, physical and emotional functioning. Up to 13.7% missed a work day (UF) 
and between 10.8% (QT) and 16.8% (UF) visited their health care provider as a 
result of MP Compared to respondents in the other countries (N= 1404), Canadian 
respondents were reported significantly longer recovery times for returning to 
normal blood glucose levels following a MP and were significantly more likely 
to experience hyperglycemia following UF/QD than patients in other countries 
(p< .05). ConClusions: These findings suggest that MPs have economic implica-
tions, impact patients’ functioning and well-being and may be serious obstacles 
to optimal diabetes control.
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objeCtives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. The purpose of this study 
was to examine these impacts in the UK and compare these findings to data 
from US, Germany, Canada, and China). Methods: A 5 country web-based survey 
examining MPs was conducted. MPs were defined as: unintentionally forgetting 
(UF) to take insulin, questioning whether or not insulin had been taken (QT), or 
questioning amount of insulin dose (QD). Results: A total of 350 UK respondents 
(52.0% Type 1), 49.1% male, mean age of 40.3, mean age of diabetes onset of 25.5 
completed the survey. The prevalence of MPs was 66.6% (UF) forgetting, 84.9% (QT) 
56.9% (QD). MPs occurred most frequently when relaxing or doing household jobs. 
Between 13.7% (UF) – 32.6% (QT) of respondents skipped their insulin dose due 
to a MP and required between 1.4 (QD)–13.1 (UF) hours, on average, to return to 
normal blood glucose range. As a result of a MP, patients conducted between 1.7 
(QT) –6.8 (UF) extra BG monitoring tests , reported a moderate negative impact on 
their physical and emotional functioning, as well as their ability to go to or func-
tion optimally at work and between 8.1% (QT) and 20.0% (UF) visited/contacted 
their health care provider . Economic implications include cost of additional BG 
strips, lost work productivity and health care resource utilization. Compared to 
respondents in the US, Germany, China and Canada (N= 1404), UK respondents 
conducted significantly more BG tests during the week following a missed dose 
of insulin were more likely to take a dose of insulin following a MP without test-
ing their BG. ConClusions: These findings suggest that MPs in the UK carry 
financial burden, impact patients’ daily functioning and well-being and may be 
serious obstacles to optimal diabetes control.
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objeCtives: To compare antidiabetic treatment compliance with regards to the 
fixed or free treatments combination. Methods: A retrospective study based on 
the IMS LifeLinkTM Diabetes Cohort linked to IMS Disease Analyzer, a longitudinal 
patient database containing the electronic health records of patients followed-up 
by a representative panel of French general practitioners. Two cohorts of patients 
treated both with metformin and DPPIV were constituted, the first one treated with 
fixed associations (“fixed cohort”), the second one treated with free associations 
(“free cohort”). Study investigated patients’ demographic and clinical character-
istics, conditions of use, persistence rates, medication possession ratio (MPR) and 
proportion of days covered (PDC) of the two cohorts. Results: Respectively 2 234 
and 8220 patients have been treated with free and fixed antidiabetic associations 
between 2007 and 2013. Patients are significantly older (66 vs. 64 years, p< 0.01) in 
the free cohort where the proportion of men is significantly lower (56% vs. 63%, 
p< 0.0001). Nevertheless diabetes oldness is the same (about 10 years) in both 
system structure and in cost transparency, the cost estimation methodology varied 
among countries. One limitation of this study is that diagnostic related group (DRG) 
tariffs were used to estimate several costs, which may not accurately represent the 
burden of a specific complication nor take into account the full burden of follow-up 
after an acute event.
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objeCtives: To assess the direct medical costs for aggressive limb preservation 
treatment of diabetic foot ulcer (DFU) in a highly-specialized hospital setting in 
Russia Methods: A retrospective data analysis of 156 admissions during 1-year 
period was done to get direct costs (associated with hospital stay, conservative 
and surgical treatment and laboratory testing) for treatment of DFU in a highly-
specialized inpatient department in Russian setting (Federal Endocrinology 
Centre). Results: The median cost of hospital treatment was 2270 EUR and 
increased with severity level, defined according to Wagner classification, ranging 
from 1590 EUR (grades 0-2) to 3812 EUR (grade 3) and 7683 EUR (grade 4), the differ-
ence was statistically significant. The length of stay in a hospital also correlated 
with the severity level starting with 14 days for grade 1 and reaching 39 days for 
grade 4. The costs of treatment were significantly higher for patients with inad-
equate vascular status requiring surgery – the median was 6185 EUR for cases with 
only angioplastic surgery and 8622 EUR for cases with both angioplastic and foot 
surgery provided. ConClusions: Treatment of DFU aimed at limb preservation is 
resource consuming, costs for treating severe stage ulcer are 4,8 times higher than 
are those for treating low-stage ulcer. The high costs of treating severe stages of 
DFU in a specialized hospital setting emphasize the value of intensive outpatient 
interventions designed to prevent ulcer progression.
DIaBeTes/enDocrIne DIsorDers – Patient-reported outcomes &  
Patient Preference studies
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objeCtives: Previous studies have shown that only a small number of pediatric and 
young adult patients discontinue pump therapy, but risk factors for discontinuation 
are unclear. Aim of this study was to identify characteristics of pediatric and young 
adult patients with pump therapy which are associated with discontinuation of 
treatment. Methods: Retrospective cohort study using a representative nation-
wide database (LRx; IMS Health) in Germany covering > 80% of all prescriptions to 
members of statutory health insurances in 2008-2011. All patients (age groups: < 6, 
6-< 12, 12-< 18, 18-< 25 years) with new prescriptions of insulin pumps or related 
material were identified (2009-2011) and were followed for ≥ 12 months. Results: 
Overall, 3057 new pump users were identified, of whom 177 (5.8%) switched to other 
forms of insulin therapy within 12 months. Discontinuation was lowest in the age 
group < 6 years (2.1%) and was highest in adolescents (12-< 18 years: 7.5%) (p< 0.01). 
In age-adjusted logistic regression, usage of steel needles (Odds ratio, OR, 95%CI: 
1.69; 1.20-2.44) and prescriptions of antiepileptics (3.14; 1.49-6.59) were related to 
pump discontinuation. In younger age groups only, discontinuation was signifi-
cantly higher in patients with thyroid therapy as a surrogate measure for thyroid 
autoimmunity (< 6 years: 14.3%; 6-< 12 years: 25.0%) (p< 0.01). ConClusions: About 
94% of pediatric and young adult patients maintained insulin pump therapy within 
12 months. Adolescence (12-18 years), usage of steel needles and prescriptions of 
antiepiletic drugs are independent predictors of discontinuation. In younger age 
groups (< 12 years) also thyroid therapy (indicating autoimmunity) was related to a 
higher risk of discontinuation.
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objeCtives: To describe persistence patterns to OHM in newly treated Irish patients 
with T2DM. The study also investigated the effect of age, gender, reimbursement 
scheme and type of OHM on persistence. Methods: A population based retrospec-
tive cohort study was conducted using national pharmacy claims databases, includ-
ing two community drugs schemes; Long Term Illness, (LTI, non-means tested) and 
General Medical Services (GMS, means tested). Newly treated T2DM patients were 
identified for 2008-2009, having received no OHM in the previous year, and followed 
up until Nov-2012. Patients who subsequently switched or received additional OHM 
were excluded. Non-persistence was defined as a prescription gap of > 12 weeks 
and within 1 year of initiating treatment. Logistic regression examined associations 
of age, gender, scheme and type of OHM with persistence with results presented 
as odds ratios (OR) and 95% confidence intervals (CI). Results: A total of 15,174 
persons were eligible for the study. Most patients were initiated on metformin 
(79.4%) and sulphonylureas (19.1%). Persistence at 1 year was 60.9%. The median 
overall time to non-persistence was 51.5 days. Men were slightly more likely to 
be persistent than women (OR= 1.08; 95%CI= 1.001 to1.15; p= 0.0025). Patients aged 
16-44 and 75+ were less likely to be persistent than patients aged 55-64 (OR= 0.18; 
95%CI= 0.16-0.21; p< 0.0001 and OR= 0.67; 95%CI= 0.60-0.75; p< 0.0001 respectively). 
Patients registered with the LTI Scheme were more likely to be persistent than 
from the GMS Scheme (OR= 1.35; 95%CI= 1.20-1.51; p< 0.0001). Patients initiated on 
